Gene expression of the human Torque Teno Virus isolate P/1C1  by Mueller, Bettina et al.
Virology 381 (2008) 36–45
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roGene expression of the human Torque Teno Virus isolate P/1C1
Bettina Mueller, Alexander Maerz, Kai Doberstein, Tim Finsterbusch, Annette Mankertz ⁎
Robert Koch-Institute, FG12 Division of Viral Infections, Robert Koch-Institute, Nordufer 20, 13353 Berlin, Germany⁎ Corresponding author. Fax: +49 30 018 754 2598.
E-mail address: mankertza@rki.de (A. Mankertz).
0042-6822/$ – see front matter © 2008 Elsevier Inc. Al
doi:10.1016/j.virol.2008.08.017a b s t r a c ta r t i c l e i n f oArticle history: Torque Teno Virus (TTV) ha
Received 9 May 2008
Returned to author for revision 25 June 2008
Accepted 7 August 2008
Available online 17 September 2008
Keywords:
Anellovirus
TTV
Transcription mappings been assigned to the ﬂoating genus Anellovirus. TTV ssDNA genomes have a
size of 3.6 to 3.8 kb and display up to 30% nucleotide diversity. The pathogenic potential of TTV is under
investigation. To address a putative link of pathogenicity with the observed sequence variations, the
transcription proﬁle of P/1C1 (genogroup 1) isolated from a patient diseased with a non A–G hepatitis was
analysed. Four mRNAs were identiﬁed, which encoded the seven proteins ORF1, ORF1/1, ORF1/2, ORF2,
ORF2/2, ORF3 and ORF4. Expression of the ORF1 protein and its splice variant ORF1/1 in cell culture was
detected by an ORF1-speciﬁc antiserum. Analysis of N-terminal tagged P/1C1-encoded proteins revealed
that ORF1, ORF1/1 and ORF1/2 were localised in the nucleoli, ORF3 and ORF4 resided in the nucleoplasm,
ORF2/2 appeared either in the nucleoli or the whole nucleus while ORF2 was the only protein seen in the
cytoplasm.
© 2008 Elsevier Inc. All rights reserved.Introduction
Although human Torque Teno Virus (TTV) was discovered in 1997
by representational difference analysis from the serum of a patient
with acute post-transfusion hepatitis of unknown etiology (Nishizawa
et al., 1997), the association of TTV with disease is still unclear (Dai
et al., 2001; Hu et al., 2002; Moriyama et al., 2003). Screening for TTV
DNA in serum of healthy individuals revealed seroprevalence of up to
90% (Abe et al., 1999; Okamoto et al., 2001). Some studies suggested
that the occurrence of a disease might correlate with TTV load, co-
infection with other agents, immune status of the host (Shibayama
et al., 2001; Touinssi et al., 2001) or differences in the genomic
sequence (Leppik et al., 2007). The latter hypothesis is intriguing,
because TTV genomes display a sequence diversity of more than 30%,
which is unusually high for a DNA virus. Phylogenetic analysis
revealed 5 genogroups, which are further subdivided into several
distinct genotypes (Peng et al., 2002).
TTV is characterized by a non-enveloped, icosahedral capsid
structure of 30 nm diameter and a circular, single-stranded DNA
(ssDNA) genome with a size of 3.6–3.8 kb. TTV has been classiﬁed to
the newly established genus Anellovirus (Biagini et al., 2005), which
comprises Torque Teno Mini Virus (TTMV; 2.8–2.9 kb), Torque Teno
Midi Virus (TTMDV; 3.2 kb) and Small Anellovirus (SAV; 2.2–2.6 kb)
(Jones et al., 2005; Ninomiya et al., 2007; Takahashi et al., 2000). It was
supposed that the latter is a deletion mutant of TTMDV (Ninomiya
et al., 2007). TTV has also been identiﬁed in primates, farm animals,
cats, dogs, and tupaias (Leary et al., 1999; Okamoto et al., 2002), thel rights reserved.reported genome sizes were in general smaller than for the humans
variants and varied between 2.0 kb for cats and 2.8 kb for pigs
(Okamoto et al., 2002).
The genome organization of TTV is similar to that of Chicken
Anemia Virus (CAV) of the genus Gyrovirus, family Circoviridae. Both
viruses display a (−)ssDNA genome, which is transcribed from a single
promoter located in the untranslated region (UTR) (Kamada et al.,
2004; Suzuki et al., 2004). Mapping of transcription and expression
strategies of different TTV isolates gives a highly variable picture:
Three mRNAs of 2.9 kb, 1.2 kb, and 1.0 kb have been characterized in
VT416 infected COS1 and TYM9 infected bone marrow cells (Kama-
hora et al., 2000; Okamoto et al., 2000). Expression of six proteins
from these three mRNAs after transfection of HEL32 into 293 cells was
shown previously (Qiu et al., 2005). Additional splicing events and
intragenomic rearrangements have been mapped after transfection of
TTV isolates tth7 and tth8 into in lymphoma and T-cell leukemia cell
lines (Leppik et al., 2007).
Since knowledge about the molecular biology of TTV and its
putative contribution to pathogenicity is rather scant, we have
mapped the transcription of TTV isolate P/1C1 (genogroup 1)
isolated from a patient suffering from non A–G hepatitis (Hohne
et al., 1998). Analysis of P/1C1 transfected Huh7 cells revealed
synthesis of a fourth mRNA which was ampliﬁed previously from
TTV transfected lymphoma and T-cell leukemia cell lines (Leppik
et al., 2007) but not identiﬁed in TTV infected 293 cells. The mRNA
encodes the smallest open reading frame so far described for TTV,
ORF4. All seven P/1C1-encoded ORF proteins were expressed and
analysed for their cellular localisation. Moreover, we demonstrated
for the ﬁrst time that expression of ORF1 in cell culture leads to
production of two proteins, full-length ORF1 and its truncated splice
variant ORF1/1.
37B. Mueller et al. / Virology 381 (2008) 36–45Results
TTV isolate P/1C1 was isolated from a patient with non A–G
hepatitis. A plasmid encoding the entire sequence but 68 bp wasFig. 1. Construction of the full-length genome of P/1C1. (A) pGEM/TTVKus contains the
incomplete genome of P/1C1 (nt 181 to 3756 and nt 1 to 113). (B) A ﬁll-in reaction
according to the sequence published in GenBank AF298585 (shaded boxes) led to
plasmid pGEM/TTVKus2a, carrying the full-length genome with a 10 bp overlap (nt 104
to 3756 and nt 1 to 113). (C) Excision and reinsertion created pGL3-P/1C1, from which
P/1C1 can be mobilized by a KpnI digest and subsequent religation.kindly given to us by Dr M. Hohne (Robert Koch-Institute, FG15). After
reﬁlling the gap between pos. 113 and 181, the genomic sequence was
excised from pGL3-P/1C1, religated and used for transfection in cell
culture experiments (Fig. 1).
Mapping of transcripts of isolate P/1C1
Previous studies demonstrated the existence of three spliced
mRNAs in TTV infected cells (Kamahora et al., 2000; Leppik et al.,
2007; Okamoto et al., 2000; Qiu et al., 2005). Moreover, it was
suggested that transcription of distinct genetic variants of TTV might
be regulated cell-type speciﬁcally (Kamada et al., 2004; Suzuki et al.,
2004). Therefore, the transcription of isolate P/1C1 was mapped in
Huh7 cells, which have been previously described to provide the
setting for a high activity of the TTV promoter (Suzuki et al., 2004). The
absence of other contaminating TTV variants in these cells was
demonstrated with a diagnostic UTR-A PCR (data not shown) (Biagini
et al., 2001).
The religated and thereby circularised genome of P/1C1 was
transfected into Huh7 cells. After 48 h, the mRNAwas transcribed into
cDNA, which was ampliﬁed with gene-speciﬁc primers (GSP) and
adapter primers (AP) hybridizing to the modiﬁed cDNA ends. The
ampliﬁed fragments were sequenced and analysed for their splice
patterns. The primer combination used and their resultant ampliﬁca-
tion products are shown in Fig. 2A.
A 5′-RACE with AP 5#2 and GSP 992 revealed transcript a, inwhich
exon 1 extended to the splice donor site 1 (SD1, nt 183; all positions
refer to the genomic sequence of P/1C1), which was fused to splice
acceptor site 1 (SA1, nt 282). These SD1/SA1-dependent splice events
were seen in all P/1C1-encoded mRNAs. The transcription start point
(Fig. 2B) was mapped by 5′-RACE using GSP 992 and AP 5#2 and
subsequent cloning. In nine of twelve clones, transcription started at
nt 111 and in three at nt 129 (transcripts a1 and a2, Fig. 2B). Both start
points are located downstream of the TATA-Box (A82TATAA) and the
capping-site C108TGAGTT, supporting previous ﬁndings (Kamada et al.,
2004) that all TTV-encoded transcripts originate from the same
promoter.
To map the 3′-ends of P/1C1-speciﬁc mRNAs, cDNAwas ampliﬁed
in a 3′-RACE with AP 3#2 and GSP 914, 963 and 962. Ampliﬁcation
with GSP 914 resulted in transcript b spanning from nt 1694 to 2994,
while ampliﬁcation with GSP 963 revealed transcript c comprising
nt 2268 to 2994. Interestingly, the use of GSP 962 revealed no
continuous fragment but a spliced transcript in which SD3 (nt 706)
was fused to SA3 (nt 2500). In three separate ampliﬁcations no
continuous fragment was observed and 3′-ends were mapped to nt
2994, indicating that transcripts are polyadenylated at the same site
(Fig. 2C).
To identify additional splice sites used in P/1C1 transcription,
cDNA ampliﬁcation was performed with the outwardly-located GSP
960 and 797. In this case the transcripts e and f were obtained. Exon
1 extended to SD1 (nt 183), which was fused to SA1 (nt 282)
supporting the results observed in the 5′-RACE. Exon 2 started at SA1
and ended either at SD2 (nt 394) in transcript e or at SD3 (nt 706) in
transcript f. In transcript e SD2 was fused to SA3 (nt 2500), in
transcript f a longer exon 2 ending at SD3 was joined to SA3. GSP 960
and 994 revealed transcript g, in which SD3 was fused to SA2 (nt
2307). Next we tested whether a continuous transcript encoding the
predicted ORF1 and ORF2 protein was produced in P/1C1 in Huh7
cells. cDNA was ampliﬁed with GSP 960 and 908 as well as GSP 915
and 797. GSP 908 and 915 were speciﬁcally designed to detect run-
through transcripts containing only the SD1/SA1 junction. In
transcript h (GSP 960/908) SD1 was fused via SA1 to exon 2, which
extends from nt 282 to 2287 (GSP 908 priming site). The actual 3′-
end of this transcript was identiﬁed using GSP 914 and AP 3#2
(Fig. 2A, transcript b). The existence of a full-length transcript was
furthermore supported by the use of inwardly located GSP 915 and
Fig. 2. cDNA analysis of P/1C1. (A) Mapped transcripts. A linear sketch of the P/1C1 genome including splice sites, TATA box, and polyadenylation site is indicated at the top. Transcripts
are given as solid lines, introns as dotted lines. The primers used for 5′-RACE, 3′-RACE and cDNAmapping are indicated. (B) Mapping of the 5′-end of the P/1C1 transcripts a1 and a2.
The genomic sequence with the TATA box is given above, cDNA ends below. (C) Mapping of the 3′-end of the P/1C1 transcripts b, c and d. (D) Alignment of the cDNA sequences
identiﬁed for P/1C1 transcription with the consensus sequences for the splice donor (SD) and splice acceptor (SA) site.
38 B. Mueller et al. / Virology 381 (2008) 36–45797, the resultant fragment extended from nt 1992 to 2784
(transcript i). Taken together, our results present evidence for the
expression of at least four spliced transcripts with a size of 2.8 kb,
1.2 kb, 1.0 kb and 0.6 kb. All three SDs and SAs were highly conserved
(Fig. 2D) and the junction SD1/SA1 was observed universally in all
ampliﬁed fragments. Our results support the use of the recently
identiﬁed SD2 in P/1C1.Prediction of viral proteins
The transcripts synthesized by P/1C1 (Fig. 3A) encoded six ORFs
(ORF1, ORF1/1, ORF1/2, ORF2, ORF2/2 and ORF2/3) identically to
those recently described (Qiu et al., 2005). In addition, the 0.6 kb
transcript encoded a truncated version of ORF2/3, also switching
from reading frame 2 to 3. To avoid confusion, ORF2/3 expressed
Fig. 3. Transcription proﬁle and protein expression of P/1C1. (A) A map of P/1C1 and the seven ORFs is shown. Coloured boxes indicate the three distinct reading frames. (B) P/1C1
proteins were expressed in vitro from the respective plasmid constructs and analysed by immunoblotting with anti-c-Myc antibody. (M) Precision Plus Protein Standard (BIORAD), (1)
negative control (vector pGBKT7), (2) pGBKT7-ORF1, (3) pGBKT7-ORF1/1, (4) pGBKT7-ORF1⁎ (splicing of ORF1 disabled), (5) pGBKT7-ORF1/2, (6) pGBKT7-ORF2, (7) pGBKT7-ORF2/2,
(8) pGBKT7-ORF3, and (9) pGBKT7-ORF4. P/1C1-speciﬁc protein bands are indicated by arrows. The expression of ORF1 and ORF1⁎ is also shown in the downward panel with
increased contrast.
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ORF2/3 version encoded by the 0.6 kb transcript was named ORF4
(Fig. 3A). The 2.8 kb transcript of P/1C1 encoded the putative ORF1
(733 aa) and ORF2 (120 aa). ORF1 displayed a 68 aa Arg-rich stretch
at the N-terminus similar to those present in the capsid proteins of
Porcine circovirus (PCV) type 1 and type 2. In addition, rolling-circle
replication motifs were located at aa 124–126 (motif I: FTL) and at aa
349–352 and 430–433 (motif III: YXXK), while motif II seemed to be
less conserved or lost. Based on these features, one might speculate
that TTV ORF1 functions as a replicase. In ORF2, the motif
WX7HX3CXCX5H was found at aa 16–36 (Erker et al., 1999; Hijikata
et al., 1999). It was previously described for TTV and CAV. ORF2 was
recently found to suppress the NFκB pathway (Zheng et al., 2007) by
preventing the p50 and p65 subunits from entering the nucleus dueto the inhibition of IκBα protein degradation. The 1.2 kb transcript
encoded ORF1/1 and ORF2/2, in which splicing altered the length of
the proteins but did not change the reading frame. ORF1/1 (199 aa) is
truncated, while ORF2/2 (284 aa) is an elongated version of ORF2.
ORF1/1 carries 41 aa of the Arg-rich ORF1 N-terminus plus the last
158 aa of the C-terminus, the Rep-motifs are lost, hinting that this
protein might not be involved in replication. In ORF2/2, the
WX7HX3CXCX5H motif was fused to a C-terminal Ser-rich stretch
neighbouring an Arg/Lys-cluster, the latter showing homology to the
human C-promoter binding factor-1 interacting corepressor and the
DNA topoisomerase I protein of Drosophila melanogaster (Takahashi
et al., 2000). This led to the speculation that ORF2/2 may serve as
DNA- or RNA-binding protein involved in transcription or replica-
tion (Tanaka et al., 2001). ORF1/2 and ORF3 were encoded by the
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joined to the C-terminus of ORF2/2 comprising the Arg/Lys-rich
region plus the Ser-rich stretch. The ORF3 (278 aa) combined the
WX7HX3CXCX5H motif with a Pro-rich C-terminus. ORF4 (173 aa)
was expressed from the small 0.6 kb transcript. In comparison to
ORF3, the ORF2 moiety is truncated while the Pro-rich C-terminus
also found in ORF3 is present.
Expression of viral proteins in vitro
To demonstrate synthesis of the seven encoded proteins and to
determine their molecular weight, the N-terminal Myc-tagged pro-
teins were expressed in vitro and detected with an anti-Myc antibody
(Fig. 3B). The size of ORF1 and an engineered variant ORF1⁎ was
approximately 80 kDa and thereby consistent with the predicted size
of 85.6 kDa. The observed sizes of the other viral proteins were: 27 kDa
(predicted size 23.7 kDa) for ORF1/1, 25 kDa (16.8 kDa) for ORF1/2,
19 kDa (12.5 kDa) for ORF2, 40 kDa (30.3 kDa) for ORF2/2, 37 kDa
(30.1 kDa) for ORF3 and 27 kDa (19.5) for ORF4. With the exception of
ORF1, the apparent sizes of the proteins were slightly higher than
predicted.
Detection of ORF1 in cell culture by TTV-speciﬁc AK47 antiserum
Since detailed expression analysis of ORF1 had not yet been
reported, ORF1, ORF1/1 or ORF1⁎ were cloned into pCMV-HA and
expressed in Huh7 cells. ORF1⁎ is an engineered version of ORF1, in
which mutagenesis of SD3 prevents splicing. Protein expression
from these plasmids in Huh7 cells was analysed by Western blot
with antiserum AK47. AK47 was raised against the C-terminal aa
402–733 of ORF1 of P/1C1, it does not react with other TTV-encoded
proteins (A. Maerz, to be published elsewhere). The use of AK47
indicated that pCMVHA-ORF1 expressed the full-length protein plus
the truncated splice variant ORF1/1 (Fig. 4A, lane 2), pCMVHA-ORF1/
1 expressed the smaller protein ORF1/1 (lane 3) while pCMVHA-
ORF1⁎ resulted in synthesis of ORF1 only (lane 4). To compare theseFig. 4. Immunological staining of ORF1 proteins. (A) Detection of recombinant ORF1 protei
HA (negative control) (2), pCMVHA-ORF1 (3), pCMVHA-ORF1/1 (4), pCMVHA-ORF1⁎ (splic
protein extracts were resolved by SDS-PAGE and analysed by Western blotting. (M) Precis
expression of ORF1. Huh7 cells were transfected with the circularised P/1C1 genome, pCMV
conjunction with an anti-rabbit FITC conjugate. Analysis was performed at 20-fold magniﬁ
1 and pCMVHA-ORF1⁎.results with the expression of ORF1-encoded proteins in the context
of viral replication, Huh7 cells were transfected with the circu-
larised P/1C1 genome (Fig. 4A, lane 5). The expression of ORF1
proteins in these cells was not detected by Western blotting with
AK47. The same result was observed in 293 and HeLa cells (data not
shown).
In addition, expression of ORF1 was analysed by immune ﬂuo-
rescence assay (IFA) in cell culture (Fig. 4B). Huh7 cells were trans-
fected with pCMVHA-ORF1, pCMVHA-ORF1/1, pCMVHA-ORF1⁎ as
well as with circularised P/1C1. Mock-transfected cells served as a
negative control. IFA was performed with antiserum AK47 and a FITC-
conjugated secondary antibody. ORF1 and ORF1/1 were seen in dots
within the nucleus, regardless whether they were expressed from the
virus or from plasmid pCMVHA. A difference was observed for the
frequency of positive cells, since ectopic ORF1 protein expression
resulted in a higher number of positive cells than expression by P/1C1.
This suggests that P/1C1 mediated ORF1 expression might be more
stringently regulated.
Cellular localisation of P/1C1-encoded proteins
All seven P/1C1-encoded ORFs were cloned into pCMV-HA and
analysed by confocal microscopy. N-terminal HA-tagged TTV-encoded
proteins were expressed in Huh7 cells (Fig. 5A) and detected with
anti-HA. Mock-transfected Huh7 cells served as a negative control.
Counterstaining with a mouse anti-nucleoli monoclonal antibody
demonstrated localisation of the ORF1, ORF1/1, and ORF1/2 proteins in
the nucleoli. The same result was observed for the engineered variant
ORF1⁎. ORF2 was distributed throughout the cytoplasm in a reticular
structure. ORF2/2 was seen either in the nucleoli or in the nuc-
leoplasm. Magniﬁcation demonstrated a granular punctiform locali-
sation of ORF2/2 resembling a distribution to nuclear speckles. ORF3
and ORF4 were detected in the nucleoplasm.
Our result differed from previously published ﬁndings, which
described localisation of ORF1 of isolate HEL32 of genogroup 1 in the
cytoplasm (Qiu et al., 2005). To investigate whether the aa sequencens by Western blot analysis with AK47 antiserum. Huh7 cells transfected with pCMV-
ing disabled) (5) or circularised P/1C1 (6) were harvested 48 h post-transfection and
ion Plus Protein Standard (BIORAD), (B) Comparison of virus-mediated and transient
HA-ORF1, pCMVHA-ORF1/1 and pCMVHA-ORF1⁎ and stained with AK47 antiserum in
cation for P/1C1 and pCMVHA-ORF1 and at 63-fold magniﬁcation for pCMVHA-ORF1/
Fig. 5. Subcellular localisation of P/1C1 proteins in Huh7 cells. (A) Huh7 cells were transfected with pCMV-HA constructs expressing the recombinant P/1C1 proteins. pCMV-HAwas
used as negative control. Nucleoli were labelled with an anti-human nucleoli antibody and visualized with a rhodamine-conjugated secondary antibody (ﬁrst panel, red signal).
P/1C1-encoded proteins were detected with an anti-HA FITC-conjugated antibody (second panel, green signal). Yellow signals in the third panel, merge of both channels,
indicate nucleolar localisation of viral proteins. The analysis was performed at 63-fold magniﬁcation. 252-fold magniﬁcation was used to improve the analysis of ORF2/2
localisation. (B) Subcellular localisation of ORF1(P/1C1) and ORF1(J01B6) as EGFP-tagged expression constructs in cell culture. Anti-human nucleoli antibody was used to stain
the nucleoli. Confocal microscopy was performed at 63-fold magniﬁcation, and images were taken at a zoom of ×2–×3. The column labelled either “anti-HA” or “EGFP” show
TTV protein expression in green, the column labelled “anti-human nucleoli” shows the nucleoli counterstained in red. The merged images indicate protein localisation in the
nucleoli.
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the targeting, ORF1 of P/1C1 and from the distant isolate J01B6 of
genogroup 5 (aa homology of 57.3%) were fused to EGFP. After 48 h,
localisation of orf1-encoded proteins was seen uniformly in the nuc-
leoli. This result demonstrates that ORF1 is localised in the nucleoli
regardless whether it was expressed transiently or from the viral
genome (Fig. 5B).
Computer-assisted analysis of SD2
To assess whether ORF4 might be expressed in other TTV
genotypes, the SD2 regions of the ﬁve genogroups were aligned
(Table 1) and correlated to the health status of the patient. No
sequence matched the consensus (A/C)AGG0T(A/G)AGT perfectly. Bestmatches to the SD-consensus with 6 of 9 nts were found in P/1C1,
TCHN-D1, and CT25F (the latter a non-diseased patient) in which the
canonical nts G−1, A+2 and G+4 were seen (Table 1). Best conformity to
the sequence of P/1C1was found for tth7, tth8, SANBAN and JT33F (the
two latter from non-diseased patients), while SD2 was less conserved
in TYM9 (3/9) and J01B6 (4/9), suggesting that SD2 may not be used
generally in all TTV variants.
The 0.6 kb mRNA has been detected for only three isolates, and if
investigation of the transcription proﬁle had been performed at all, it
was done by methods of different sensitivity. Thus, the 0.6 kb mRNA
was neither detected by Northern Blot in VT416 infected COS1 cells
(genogroup 1) (Kamahora et al., 2000), nor by themore sensitive RACE
for TYM9 infected bone marrow cells (genogroup 3) (Okamoto et al.,
2000). At the moment, the lack of information clearly prevents
Table 1
Splice donor sites of different TTV genotypes in comparison to the consensus sequence
Genogroup Isolate State of health Position of putative SD2 Sequence Technique for identiﬁcation of transcripts Reference
1 P/1C1 Non A–G hepatitis 394 RACE Hohne et al. (1998)
TA278 Post-transfusion hepatitis 400 ATGGTACTC Northern Blot (NB) Okamoto et al. (1998)
HEL32 Non-symptomatic 401 CTGGTTCGC NB/RNase protection assay Kakkola et al. (2002)
VT416 Post-transfusion hepatitis 400 ATGGTACTC NB Kamahora et al. (2000)
2 KAV HCV infection 394 CTGGTACAC Computer-assisted sequence analyses (CA) Heller et al. (2001)
PMV Non A–E hepatitis 375 CCGGTATAC CA Hallett et al. (2000)
Kt-10F Healthy 382 AATGTACCC CA Muljono et al. (2001)
3 TUS01 Blood donor 385 ATGGTTCGC CA Okamoto et al. (1999)
SANBAN Healthy 403 CA Hijikata et al. (1999)
TYM9 Acute myeloblastic leukemia 399 GCTGTGTTA RACE/NB Okamoto et al. (2000)
4 CT25F TTV-positive 393 GCGGTGAGT CA Peng et al. (2002)
JT14F TTV-positive 392 GCGGTGAGC CA Peng et al. (2002)
5 JT33F TTV-positive 385 CA Peng et al. (2002)
J01B6 Non A–G hepatitis 400 CTGGTTCCA CA Unpublished
TCHN-D1 Hepatitis 378 GAGGTATGG CA Luo et al. (2002)
tth7/tth8 Hodgkin's disease 389 RACE Jelcic et al. (2004)
Consensus sequence
Underlined letters represent the core nucleotides GT of the splice donor consensus sequence; bold letters indicate nucleotides matching the consensus sequence. Boxed letters
display conserved nucleotides in SD2 of tth7, tth8, JT33F, SANBAN and P/1C1.
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transcription analysis of more TTV isolates.
Discussion
Although many reports describe detection and epidemiology of
TTV, molecular characterization of the ﬁrst ssDNA viruses detected in
humans is only scarcely reported. To improve our knowledge in gene
expression of the different TTV isolates, isolate P/1C1 of genogroup 1
was characterized for its transcription, protein expression and protein
localisation by transfection of Huh7 cells with a genomic clone of
P/1C1. Huh7 cells were chosen because enhanced transcription
activity of isolate SANBAN has been described in this cell line (Suzuki
et al., 2004). We have conﬁrmed synthesis of three mRNAs, 2.8 kb,
1.2 kb and 1.0 kb, already described for HEL32 (Qiu et al., 2005).
Additionally, a 0.6 kbmRNAwasmapped, whose splice transition sites
was observed recently in lymphoma and T-cell leukemia cell lines
after transfection with TTV (Leppik et al., 2007). The 5′-ends of the
P/1C1 transcripts were mapped downstream of the TATA box
(T83ATAA) and the capping-site (C108TGAGTT) to nt 111 and 129,
coinciding with promoter and enhancer elements that have been
mapped for the isolate VT416 (genogroup 1) in K562 cells (human
erythroleukemia) (Kamada et al., 2004) and promoter activity
detected for a fragment upstream of the transcription initiation site
of isolate SANBAN (genogroup 3) in Huh7 cells (Suzuki et al., 2004).
The 3′-end of the transcripts was seen uniformly at nt 2994
downstream of the poly(A) signal (nt 2971 to 2976). Three splice
donor and acceptor sites (SD1–3, SA1–3) were involved in production
of the four distinct mRNA species. The ﬁrst splice event joining SD1 to
SA1 is ubiquitously used in all TTV genotypes. The splice junction SD2/
SA3 was detected by 3′-RACE as well as by 5′-RACE and resulted in
formation of the 0.6 kb mRNA. This small transcript encodes a short
protein in which frame 2 shifted to frame 3, identical to transcript d
described for tth7 and tth8 (Leppik et al., 2007). A slightly longer
ORF2/3 protein is expressed from the 1 0 kb mRNA. To distinguish the
two versions of ORF2/3, we have denominated them ORF3 and ORF4.
To assess whether the expression of ORF4 might be linked to
pathogenesis, the sequences of several representative TTV isolates
from distinct genogroups and diseased or healthy persons were
aligned. SD2was conserved in isolates P/1C1, tth7, and tth8, all derived
from diseased individuals but also in JT33F and SANBAN, isolated from
healthy persons. In other TTV isolates, SD2 was less conserved. The
0.6 kb transcript was detected for P1/C1, tth7, and tth8 but not for
isolates TYM9 and VT416 (Kamahora et al., 2000; Okamoto et al.,2000). Since this difference could be attributed either to a missing
splice event or to the different sensitivity of the applied methods, our
observations demonstrate that a thorough investigation of gene
expression from more TTV isolates is necessary.
Expression of orf1-encoded proteins was investigated by ectopic
expression of HA-tagged ORF1 as well as from P/1C1 in cell culture by
Western blot and IFA. Immunoblotting with ORF1-speciﬁc AK47 anti-
serum demonstrated synthesis of two proteins from pCMVHA-ORF1,
the full-length ORF1 and the spliced ORF1/1. The shorter ORF1/1
protein was expressed more prominently, corroborating an earlier
observation made for Porcine circovirus (PCV), where the shorter Rep′
protein was more strongly expressed than the full-length Rep protein
(Mankertz and Hillenbrand, 2001). To our knowledge, detection of
ORF1 and ORF1/1 byWestern blot is reported here for the ﬁrst time. In
P/1C1 transfected Huh7, HeLa, and 293 cells expression of ORF1 or
ORF1/1 was not detected by Western blotting, corroborating recent
reports for isolate HEL32 (Qiu et al., 2005). In contrast, ORF1
expression was demonstrated by IFA with antiserum AK47 in P/1C1-
transfected Huh7 cells. This apparent contradiction may be attributed
to the fact, that expression of ORF1 by the P/1C1 promoter seems to be
more tightly regulated than expression from the heterologous CMV
promoter, since we observed that ORF1-positive cells showed the
same intensity of the ﬂuorescence signal but the number of positive
cells was lower. This effect could dilute the Western blot signal below
the level of detection. Localisation of the HA-tagged viral proteins
were analysed in Huh7 cells. ORF1, ORF1/1 and the ORF1/2 resided
within the nucleoli. A similar localisation pattern was observed after
expression of ORF1 from P/1C1 and detected by antiserum AK47. Our
ﬁndings did not conﬁrm previously reported localisation of ORF1 in
the cytoplasm or ORF1/1 in the cytoplasm and the nucleus (Qiu et al.,
2005). Nevertheless, our results are supported by the presence of the
Arg-rich N-termini (M1AYGWWGRRRRWRRWRTRRRPWRTRRR-
RRRRAPRRFRPRRR41) in ORF1, ORF1/1 and ORF1/2 proteins, which
display homology to the nucleolar localisation signals (NuLS) of
Adenovirus protein V (Matthews, 2001) or oncogene MEQ of Marek's
disease virus (MDV) (Liu et al., 1997). Nucleoli are involved in many
cellular events including ribosome biogenesis, cell cycle regulation
and gene silencing (Hiscox, 2002;Mayer, 2001) and interaction of viral
proteins with nucleolar components during transcription or replica-
tion has been reported (Matthews, 2001; Mayer, 2001; Finsterbusch
et al., 2005). We have seen nucleolar localisation of ORF1 of isolates
P/1C1 and J01B6 (genogroup 5) fused to EGFP and have also
demonstrated expression of intact ORF1 and ORF1/1 proteins by
Western blotting.
43B. Mueller et al. / Virology 381 (2008) 36–45ORF3 and ORF4 of P/1C1 were observed in the nucleus but omitted
the nucleoli. They share a common Pro-rich C-terminus, which might
be indicative of protein–protein interactions (Kay et al., 2000; Mayer,
2001; Sudol, 1998). ORF2 was localised to a reticular structure in the
cytoplasm, whereas ORF2/2 showed a variable localisation. It was seen
either in the nucleoplasm or in the nucleoli in granular structures
resembling nuclear speckles, indicating that it may shuttle during
different phases of infection. The ORF2/2 sequence shows homology to
the ‘pat4’ motif (K221KRKAPKRRCKRR233), a typical nuclear localisa-
tion signal (NLS) (Robbins et al., 1991). Targeting of ORF2/2 to nuclear
subcompartments may suggest a putative function in splicing, since
most of pre-mRNA processing factors are dynamically concentrated in
20–50 nuclear speckles (Lamond, 1999; Singer and Green, 1997).
In this study, we presented evidence for the synthesis of four
mRNAs and seven proteins from TTV isolate P/1C1, which have been
investigated for their localisation and are currently subjected to aTable 2
Sequences of the primers used for this study
Position
Oligonucleotides for hybridization
856 sense 268–301
857 sense 233–267
858 sense 203–232
861 antisense 282–306
862 antisense 247–281
863 antisense 217–246
864 antisense 182–216
866 sense 168–202
867 sense 133–167
868 sense 104–132
869 antisense 147–181
870 antisense 104–146
Gene-speciﬁc primers for RACE analysis
789 antisense 2563–2585
797 antisense 2761–2784
908 antisense 2272–2287
914 sense 1694–1714
915 sense 1992–2014
960 sense 104–123
962 sense 583–600
963 sense 2268–2286
992 antisense 351–331
994 antisense 2408–2425
Adapter primers
3#2
5#2
Primers for cloning
729 antisense 2760–2784
730 sense 581–604
733 antisense 684–709
735 antisense 2948–2975
805 antisense 2947–2975
806 antisense 2836–2855
830 sense 607–630
831 sense 589–609
878 antisense 114–134
879 sense 91–113
943 sense 586–604
984 sense 347–371
985 sense 350–371
995 antisense 2779–2803
996 antisense 2779–2804
1001 antisense 691–709
1002 antisense 691–712
1050 sense 586–604
1088 sense 681–720
1089 antisense 686–716
1127 sense 349–371
1178 sense 586–606
Underlined nucleotides represent the restrictions sites used for cloning.molecular biological characterization to deﬁne their function. Results
from our study as well as from others suggest that the gene expression
of distinct TTV isolates may vary according to their genomic sequence.
These ﬁndings underline the need for a thorough characterization of
more TTV isolates from different genotypes plus the attempt to link
this information with the putative pathogenic potential.
Material and methods
Standard procedures were followed (Sambrook et al., 2001) if not
stated otherwise.
Construction of the full-length genome of TTV isolate P/1C1
Plasmid pGEM/TTVKus contains an incomplete genome (nt 181 to
3756 and nt 1 to 113; 3688 bp) of TTV isolate P/1C1 (accession no.Sequence
5′-P-GAAGCACTTTCCTTTTCTTTCTGTAAAGTTTACCG-3′
5′-P-AGAAACATGGCTTTTTAAGAGCCTTGCCCATAGCC-3′
5′-P-CGGCCAGTCCCGAGCCCGAATTGCCCCTTG-3′
5′-P-GAAAGAAAAGGAAAGTGCTTCTGCA-3′
5′-P-CTCTTAAAAAGCCATGTTTCTCGGTAAACTTTACA-3′
5′-P-GGCTCGGGACTGGCCGGGCTATGGGCAAGG-3′
5′-P-GGTGAGTTTACACACCGCAGTCAAGGGGCAATTCG-3′
5′-P-ACTGCGGTGTGTAAACTCACCTTCGGCACCCGCCC-3′
5′-P-TCGGGACGCGCTGAGGTCCCTCCGTGGCTTCACCG-3′
5′-P-CTGCGGACGGGCGTGGAAAACTCAGCCATGAGCT-3′
5′-P-AGGGACCTCAGCGCGTCCCGAGGGCGGGTGCCGAA-3′
5′-P-CATGGCTGAGTTTTCCACGCCCGTCCGCAGCGGTGAAGCCACGG-3′
5′-TCGCTGCTGGACTCTGAAACCTGA-3′
5′-TAGGATCCTTACGCTTGGGAAGATAATAGGGG-3′
5′-CCGCCCCATTTCCAGTG-3′
5′-CCCTGCCAAACTACCCTACAA-3′
5′-CGCCATTCACCTAACTGCCAGAG-3′
5′-ATGGCTGAGTTTTCCACGCC-3′
5′-ATGGCCTACGGATGGTGG-3′
5′-ATTCCACTGGAAATGGGGC-3′
5′-CACATAATCAGAAGCCGCCTA-3′
5′-TGTCCCACGAGTGCCAGG-3′
5′-CGCGGATCCGAATTAATACGACTCACTATAGG-3′
5′-CGCGGATCCGACACTGCGTTTGCTGGCTTTGATG-3′
5′-GGCTCGAGTTACGCTTGGGAAGATAATAGGGGG-3′
5′-CCGGATCCATGGCCTACGGATGGTGGGGCC-3′
5′-GGCTCGAGTTACTCTTCGACGAGGTCGAAAGCG-3′
5′-GGCTCGAGTTATTGGAAGTTAAGTTTAAAGGAGAC-3′
5′-TAGGATCCTTATTGGAAGTTAAGTTTAAAGGAGACT-3′
5′-TAGGATCCCTACAAGAGGCAGGGATTTAC-3′
5′-GAAGATCTCGGCATGGGGATGGTGGAAACGCCGG-3′
5′-GAAGATCTCGGCCTACGGATGGTGGGGCCGCCGG-3′
5′-P-TTTCCACGCCCGTCCGCAGC-3′
5′-ACTCAGCCATTCGGAAGTGCACC-3′
5′-CGNNCATATGGCCTACGGATGGTGGGGCC-3′
5′-ATGGATCCATGTGGCAGCCCCCCGTGCACAAAG-3′
5′-ATGAATTCTGGCAGCCCCCCGTGCACAAAG-3
5′-CCGCTCGAGTCAAACATAAAGGCTTTGTTTACG-3′
5′-CGGGATCCTCAAACATAAAGGCTTTGTTTACG-3′
5′-CCGCTCGAGTTACTCTTCGACGAGGTCG-3′
5′-CGGGATCCTTACTCTTCGACGAGGTCG-3′
5′-CGGAATTCGCCTACGGATGGTGGGGCC-3′
5′-TCGCCGCACCTGCCCTCGTCGAAGAATAAGGAGGCGCAGG-3′
5′-TGCGCCCACCTGCTCTTCGACGAGGTCGAAA-GC-3′
5′-ATGAATTCGGTGGCAGCCCCCCGTGCACAAAG-3′
5′-cgagatctctGCCTACGGATGGTGGGGCCGC-3′
44 B. Mueller et al. / Virology 381 (2008) 36–45AF298585, kindly provided by Dr M. Hohne, RKI) (Fig. 1A). For
generation of a full-length P/1C1 construct, 12 overlapping oligonu-
cleotides (Table 2) corresponding to nt 104 to 306 of the genome, were
phosphorylated, hybridized, restricted with SacI/PstI and inserted into
SacI/PstI restricted plasmid pGEM/TTVKus (Hohne et al., 1998). The
resultant plasmid pGEM/TTVKus2a (Fig. 1B) was used as template in a
PCR containing primer pair 878s/879as and the TaKaRa LA polymerase
(Takara, Gennevilliers, France) to amplify the complete genome. The
PCR product of approximately 3800 bp was blunted, phosphorylated
and ligated to form concatameric or circular TTV genomes. After
restriction with KpnI (unique in P/1C1) the linearized TTV genome
were subsequently cloned via Kpn1 into pGL3-Promoter (Promega,
Mannheim, Germany). The resultant construct pGL3-P/1C1 (Fig. 1C)
was sequenced to exclude PCR-acquired mismatches. The P/1C1
genome was mobilized from this plasmid by KpnI digestion and
isolated by agarose gel electrophoresis and gel extraction (Qiagen,
Hilden, Germany). After ligation for 1 h in a volume of 100 μl at room
temperature, usually 90% of viral input DNA was converted into a
circular double-stranded DNA molecule, which corresponds to the
replicative form of TTV. This material has been used for transfection of
cells to mimic a TTV infection.
Transfection and RNA extraction
2×105 Huh7 cells (human hepatocellular carcinoma; ATCC CCL-
185) were seeded in 6-well plates and transfected with 400 ng of the
religated P/1C1 genome using Effectene (Qiagen). 48 h post-transfec-
tion RNA was harvested using the RNeasy Mini Kit (Qiagen) for total
RNA minipreps from animal tissues. RNA isolation included a DNase I
treatment with 50 U DNase I (Amersham Biosciences, Freiburg,
Germany) for 45 min at room temperature and a subsequent phenol
extraction.
cDNA cloning and characterization
cDNA synthesis was performed with SuperScript™ III reverse
transcriptase (Invitrogen, Carlsbad, USA) and the FirstChoice® RLM-
RACE Kit (Ambion Inc., Austin, USA). Reverse transcription of 1 μg total
RNA was primed with the poly(A)+ tail 3′-RACE adapter. For the
ampliﬁcation of 5′-ends, the cap-structure of 1 μg total RNA was
replaced by 5′-RACE adapter according to the manufacturer's instruc-
tions. Reverse transcriptionwas performed for 1 h at 42 °Cwith adapter
primers. For characterization of the cDNA, gene-speciﬁc primers (GSP)
and adapter primers (AP) were used (Table 2). PCR was performed with
1 μl cDNA in a volume of 50 μl and 200 nm of each primer, 10× PCR
buffer plus MgCl2 (15 mM), 200 μM (each) dNTPs and 1.0 U Ambion
SuperTaq™ Plus DNA Polymerase (Ambion Inc.). Cycling parameters
were 94 °C for 3 min, 35× (30 s, 94 °C; 30 s, annealing temperature
according to Tm of the primers; 4 min, 68 °C) 10 min, 68 °C.
Plasmid construction
PCR fragments of P/1C1 for subcloning were ampliﬁed using the
High Fidelity PCR System (Roche Diagnostics, Mannheim, Germany).
ORF1 and ORF2 were ampliﬁed from template pGEM/TTVKus,
whereas spliced ORFs were ampliﬁed from cDNA. Primer sequences
are given in Table 2 (ORF1 and ORF1/1: 730/729; ORF2: 984/1001,
ORF1/2: 730/995, ORF2/2: 984/995, ORF3 and ORF4: 984/735). PCR
products were cloned via newly introduced restriction sites into
pcDNA3.1(+) (Invitrogen) and subsequently sequenced. In ORF1⁎, an
engineered variant of ORF1, splicing was disabled by mutagenesis of
SD3 corresponding to pos. 706 (G706TA to A706TA). pcDNA-ORF1⁎ was
generated by ampliﬁcation of two fragments of ORF1 from pcDNA-
ORF1 using primer pairs 730/1089 and 1088/729 (Table 2). Primer
1088 introduced the point mutation. PCR fragments were restricted
with AarI and BamHI (730/1089) or AarI and XhoI (1088/729) andcloned into BamHI- and XhoI-restricted pcDNA3.1 (+). For subcloning
into expression vectors pCMV-HA or pGBKT7 (BD Biosciences
Clontech, Heidelberg, Germany) new restriction sites were introduced
via PCR using the respective pcDNA constructs as templates. For
pCMVHA-ORF1, -ORF1⁎ and -ORF1/1 primer pair 1178/729 was used
(pCMVHA-ORF1/2: 1178/995; -ORF2: 1127/733; -ORF2/2: 1127/995; -
ORF3 and -ORF4: 1127/735). The PCR products were digested with
EcoRI/BglII and XhoI, and cloned into pCMV-HA to generate N-
terminal HA-tagged proteins. For generation of pGBKT7-ORF1 and -
ORF1⁎, primers 943 and 797 were used (pGBKT7-ORF1/1: 1050/797; -
ORF1/2: 1050/996; -ORF2: 985/1002; -ORF3 and -ORF4: 805/985).
Fragments were digested with BamHI/EcoRI or BamHI/NdeI, respec-
tively, and cloned into pGBKT7 to obtain N-terminally Myc-tagged
proteins. For generation of pEGFP-constructs primer pairs 831/797
(ORF1-P/1C1) and 830/806 (ORF1-J1B6) were used. The PCR products
were digested with BamHI/BglII and cloned into pEGFP-C2.
In vitro and in vivo expression of viral proteins and immunoblot analysis
For in vitro expression of Myc-tagged proteins, the TNT wheat
germ extract system (Promega) was used according to the manufac-
turer's recommendations. 1 μg NotI linearized pGBKT7-based plas-
mids were incubated in 50 μl at 30 °C for 90 min. For in vivo
expression, pCMVHA-ORF1, -ORF1/1 and -ORF1⁎ as well as religated
P/1C1 were transfected into Huh7 cells. 48 h post-transfection, cells
were treated with Laemmli buffer containing benzonase (Gibbstown,
USA). Expression of viral proteins was analysed after SDS-PAGE by
Western blotting. After transfer onto a PVDFmembrane, proteins were
probed with monoclonal anti-c-Myc (0.7 μg/ml) (HISS, Freiburg,
Germany) in conjunction with anti-mouse peroxidase conjugate as a
secondary antibody (0.8 μg/ml) (HISS) or AK47 antiserum (1:400) with
anti-rabbit peroxidase conjugate (0.8 μg/ml) (HISS). AK47 was
generated by immunization of rabbits with a C-terminal fragment of
the ORF1 of P/1C1 (aa 402–733, A. Maerz, to be published elsewhere).
The Western Blotting detection reagent was used for detection
(Boehringer, Mannheim, Germany) and molecular weight marker
Precision Plus Protein™ Standards (BIORAD, Hercules, USA) for size
determination of viral proteins.
Fluorescence and indirect immune ﬂuorescence assay
6×104 Huh7, 5×104 HeLa, and 4×104 293 cells were seeded on glass
coverslips in 24-well plates. After incubation for 24 h, cells were
transfected with 250 ng of either the pCMVHA-based as well as pEGFP-
based ORF1 constructs or the religated full-length P/1C1 genome. 48 h
post-transfection cells were ﬁxed and permeabilised with −20 °C
methanol–acetone (1:1) for 10 min and air-dried subsequently. Cells
were blocked for 1 h with 1% BSA and 0.05% Tween 20 in PBS. For
detection of HA-tagged proteins, cells were incubated 1 h with
monoclonal anti-HA FITC-conjugated antibody (1 μg/ml) (Sigma,
Missouri, USA). Nucleoli were stained with a mouse anti-human
nucleoli monoclonal antibody (1:200) (Chemicon International, Chand-
lers Ford, USA) in conjunction with Rhodamine Red™-X-conjugated
goat anti-mouse antibody (7.5 μg/ml) (Jackson ImmunoResearch, West
Grove, USA). To detect ORF1 with a TTV-speciﬁc antiserum, cells were
incubated for 1 h with AK47 antiserum (1:400), washed and incubated
for 1 h with FITC-conjugated goat anti-rabbit antibody (10 μg/ml)
(Jackson Immuno Research). Finally, coverslips were washed and
mounted in Immu-Mount (Shandon, Frankfurt, Germany). Subcellular
localisation of viral proteins was investigated by confocal laserscanning
microscopy using a Zeiss LSM510 microscope.
Computer analysis
Database (DDBJ) searches and sequence analyses were performed
by FASTA and DNASTAR Lasergene SeqMan Pro 7.1.1. The sequence
45B. Mueller et al. / Virology 381 (2008) 36–45alignments were carried out with MacVector 8.1.1 (accelrys). TTV
genomes TA278 [GenBank accession no. AB08394], VT416
[AB050448], HEL32 [AY666122], P/1C1 [AF298585] of genogroup 1,
KAV [AF435014], PMV [AF261761], Kt-10F [AB054648] of genogroup 2,
TUS01 [AB017613], SANBAN [AB025946], TYM9 [AB050448] of
genogroup 3, CT25F [AB064596], JT14F [AB064603] of genogroup 4,
JT33F [AB064606], tth7 [AJ620230], tth8 [AJ620231] and TCHN-D1
[AF345524] of genogroup 5 were used for alignments.
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